Lv7
3950 积分 2022-04-05 加入
Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines
2天前
已完结
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
21天前
已完结
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
21天前
已完结
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
21天前
已完结
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
21天前
已完结
The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial
21天前
已完结
KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
26天前
已完结
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial
1个月前
已完结
皖公网安备34019202002308
